FDA Approves Aricept for Severe Alzheimer's Disease
Posted on: Monday, 16 October 2006, 09:00 CDT
Japanese pharmaceutical Eisai has said the FDA has approved Aricept for treatment of severe Alzheimer's disease in the US.
With this approval, Aricept becomes the first and only prescription medication to treat the full spectrum of Alzheimer's disease from mild, moderate to severe. Aricept, which is co-promoted in the US by Eisai and Pfizer, has been approved in the US since 1996 for treatment of mild to moderate Alzheimer's.
The approval was based on results of a pivotal six-month clinical trial the first to evaluate Aricept once-daily exclusively in patients with severe Alzheimer's. Patients treated with Aricept had statistically significant benefit compared to those taking placebo.
"Aricept has been proven effective and well tolerated to help treat the symptoms of mild to moderate Alzheimer's disease," said Rachelle Doody, professor of Neurology, Baylor College of Medicine. "With this approval, we now know that Aricept can provide benefit in memory, thinking and activities of daily living in people with severe Alzheimer's disease."
Alzheimer's affects about 4.5 million Americans.
Source: Datamonitor
Related Articles
- Abbott's HUMIRA(R) (Adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
- International Brain Aging Expert Challenges the Existence of Alzheimer's As a 'Disease'
- Understand Differential Treatment and Unmet Needs in Different Disease Severities
- Disease Severity of MS Families Not the Same
- Quigley Pharma Compound QR-442 Shown to Delay Onset of Disease and Lower Disease Severity in Animal Multiple Sclerosis Model
- Eisai: Aricept in for Severe Approval
- Groundbreaking Research Identifies Potential Biomarkers of Rheumatoid Arthritis Disease Severity
- Pediatric Crohn's Disease and Growth Retardation: The Role of Genotype, Phenotype, and Disease Severity
- Alzheimer's, Other Diseases Often Mistaken
User Comments (0)
RSS Feeds